Werewolf Therapeutics, Inc. HOWL
NASDAQ · United States · Health Technology
$0.9135-0.01 (-0.95%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
A merger and a $150 million capital infusion is giving Werewolf's next chapter more firepower, but investors still face risks.
Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares?
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Werewolf Therapeutics Inc (NASDAQ:HOWL) shares soared 120% in premarket trading on Friday after the biotechnology company agreed to merge with Ambros Therapeutics Inc alongside a $150 million private placement. The all-stock combination will create a company centred on the development of neridronate, Ambros Therapeutics’ late-stage drug candidate for Complex Regional Pain Syndrome Type 1 (CRPS-1).
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.